Fidmi Medical Raises US$2 Million from B. Braun Melsungen AG

Misgav, Israel – 25 September 2017 – Fidmi Medical Ltd. ("Fidmi"), a portfolio company of The Trendlines Group ("Trendlines") (SGX: 42T; OTCQX: TRNLY), announced that it received an investment of US$2 million from B. Braun Melsungen AG ("B. Braun").

Fidmi Medical has developed a new low-profile enteral feeding device (nutrition through a tube) that overcomes the drawbacks of existing solutions. Current feeding tubes are changed often due to clogging, degradation or dislodgement. The Fidmi device has a replaceable inner tube that keeps the feeding line fresh and prevents clogging. Its soft, stable internal structure prevents unexpected dislodgements. Upon removal, the internal structure gently disassembles to eliminate damage to the stoma tract and surrounding tissue, preventing unnecessary hospital visits and dramatically improving patient quality of life.

Enteral feeding is common in people who cannot receive nutrition and medication orally. Annually, there are approximately 1.3 million enteral device insertions worldwide, and some 3 million replacement procedures for blocked or dislodged tubes.[1] The market seeks an enhanced enteral feeding device that stays securely in place and maintains tube patency during treatment for improved patient safety and reduced hospitalization costs.

Fidmi CEO, Shahar Millis, remarked: "We believe that Fidmi's enteral feeding tube will make a real difference to patients and caregivers. The investment by B. Braun affirms their confidence in the company and its achievements; we're excited to have begun human trials and soon bring our product to a market eagerly awaiting better solutions."

Investment funds will be used to complete clinical trials and prepare for market entry.

"Fidmi Medical is a great example of a company that fulfills our mission of creating and developing companies to improve the human condition, added Todd Dollinger, Chairman and CEO, The Trendlines Group -- a major shareholder in Fidmi. "Their product truly makes a huge difference to millions of people who live with the day-to-day challenges of feeding tubes,"

"Investing in Fidmi Medical," said Dr. Meinrad Lugan, member of the B. Braun Management Board, "is an exciting opportunity for B. Braun to contribute in easing patients' and medical specialists' challenges in enteral feeding, thereby not only significantly increasing patient's comfort but also making related clinical processes safer and much more efficient. Our engagement in Fidmi, a portfolio company of Trendlines, further reinforces the successful cooperation between Trendlines and B. Braun."

[1] Global Data Research, 2016

About The Trendlines Group Ltd.

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfill its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX (OTCQX: TRNLY).

About B. Braun

With over 56,000 employees in 64 countries, B. Braun is one of the world's leading manufacturers of medical devices and pharmaceutical products and services. Through constructive dialogue, B. Braun develops high quality product systems and services that are both evolving and progressive – and, in turn, improves people's health around the world. In 2015, the group generated sales of approximately €6.13 billion.

Investor Contact Information

Israel:
Judith Kleinman, Director, Investor Relations & Corporate Communications
The Trendlines Group
judith@trendlines.com
Tel: +972.72.260.7000

Singapore and China:
Reyna MEI, Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

The Trendlines Group Ltd. (the "Company") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "SGX-ST") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor").

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).